ACLX
BEARISH
$114.39
Live
Arcellx, Inc. · NASDAQ
Target $111.07
(-2.9%)
$47.86
52W Range
$114.8
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$6.69B
P/E
N/A
ROE
-53.4%
Profit margin
N/A
Debt/Equity
0.13
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
88%
ACLX exhibits severe financial distress despite a strong technical trend and recent insider selling. The Piotroski F-Score of 1/9 indicates extremely weak financial health, with negative profitability metrics across all dimensions—operating margin at -3850.24%, ROE at -53.42%, and a revenue decline of -89.20% YoY. The absence of an Altman Z-Score raises bankruptcy risk concerns, while the Graham Number and intrinsic value are unavailable, suggesting no reliable defensive valuation. The stock trades at a massive premium with a Price/Sales of 300.17 and Forward P/E of -71.60, reflecting speculative growth expectations rather than fundamentals.
Key Strengths
Strong technical trend (10/100) indicating short-term bullish momentum
Recent quarters have shown positive earnings surprises (e.g., +69.5%, +184.0%)
High insider activity in recent quarters (though all sales)
Market cap of $6.69B places it among mid-tier biotech players
Analyst consensus holds a 'hold' recommendation, indicating cautious optimism
Key Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and poor operational efficiency
Negative operating margin (-3850.24%) and zero profit margin indicate unsustainable business model
Revenue declined 89.20% YoY, signaling core business contraction
Insider selling of $17.36M in last 6 months reflects bearish sentiment from leadership
No positive cash flow or profitability metrics; high valuation multiples unsupported by fundamentals
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
18
Weak
15
25
40
10
0
AI Verdict
weak
Key drivers: Extremely low Piotroski F-Score, Negative profitability and revenue growth, High valuation multiples with no earnings support, Bearish insider activity, Lack of financial health indicators
Confidence
88%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
No standout positives identified.
Watchpoints
- Price/Sales of 300.17 is astronomically high
- Forward P/E of -71.60 indicates no earnings
- Graham Number and intrinsic value unavailable
- No defensive fair value support
Future
25/100
Ref Growth rates
Positives
- Recent positive earnings surprises in 3 of last 4 quarters
- High growth expectations embedded in valuation
Watchpoints
- Revenue growth down 89.20% YoY
- Earnings growth negative and worsening
- No sustainable path to profitability
Past
40/100
Ref Historical trends
Positives
- Some quarters beat estimates (e.g., +184.0% surprise in Q4 2023)
- Improvement in EPS surprise from -557.6% to +3.4% in recent quarters
Watchpoints
- Historical earnings surprises include massive misses (e.g., -557.6%, -135.8%)
- Consistent negative EPS with no profitability trend
- Q/Q EPS growth at -2.0%, indicating deterioration
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Debt/Equity ratio of 0.13 is low
- Current and quick ratios of 4.43 and 4.32 indicate strong liquidity
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial distress
- No Altman Z-Score available, but low score implies distress risk
- Negative ROE, ROA, and ROIC suggest poor capital efficiency
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout
- Dividend strength score of 0/100
- No history of dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$114.39
Analyst Target
$111.07
Upside/Downside
-2.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACLX and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACLX
Arcellx, Inc.
Primary
|
+580.9% | +279.9% | +59.8% | +50.1% | +63.7% | +0.1% |
|
HQY
HealthEquity, Inc.
Peer
|
+11.9% | +34.2% | -2.5% | -13.9% | -0.8% | -7.9% |
|
RGEN
Repligen Corporation
Peer
|
-39.7% | -30.0% | -7.4% | -11.9% | -5.7% | +1.3% |
|
GRFS
Grifols, S.A.
Peer
|
-51.1% | +11.6% | +28.0% | -11.9% | +2.2% | -0.4% |
|
KYMR
Kymera Therapeutics, Inc.
Peer
|
+170.6% | +171.2% | +279.7% | +48.7% | +4.3% | -0.4% |
ACL
Arcellx, Inc.
Primary
5Y
+580.9%
3Y
+279.9%
1Y
+59.8%
6M
+50.1%
1M
+63.7%
1W
+0.1%
HQY
HealthEquity, Inc.
Peer
5Y
+11.9%
3Y
+34.2%
1Y
-2.5%
6M
-13.9%
1M
-0.8%
1W
-7.9%
RGE
Repligen Corporation
Peer
5Y
-39.7%
3Y
-30.0%
1Y
-7.4%
6M
-11.9%
1M
-5.7%
1W
+1.3%
GRF
Grifols, S.A.
Peer
5Y
-51.1%
3Y
+11.6%
1Y
+28.0%
6M
-11.9%
1M
+2.2%
1W
-0.4%
KYM
Kymera Therapeutics, Inc.
Peer
5Y
+170.6%
3Y
+171.2%
1Y
+279.7%
6M
+48.7%
1M
+4.3%
1W
-0.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-71.6
PEG Ratio
N/A
P/B Ratio
16.47
P/S Ratio
300.17
EV/Revenue
282.29
EV/EBITDA
-25.53
Market Cap
$6.69B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-3850.24%
Gross Margin
N/A
ROE
-53.42%
ROA
-24.05%
Growth
Revenue and earnings growth rates
Revenue Growth
-89.2%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.13
Low debt
Current Ratio
4.43
Strong
Quick Ratio
4.32
Excellent
Cash/Share
$7.7
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-26
$-1.01
+3.4% surprise
2025-11-05
$-0.99
+4.1% surprise
2025-08-07
$-0.94
+8.9% surprise
Healthcare Sector Comparison
Comparing ACLX against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-53.42%
This Stock
vs
-101.52%
Sector Avg
-47.4%
(Below Avg)
Debt to Equity
0.13
This Stock
vs
3.4
Sector Avg
-96.2%
(Less Debt)
Revenue Growth
-89.2%
This Stock
vs
124.21%
Sector Avg
-171.8%
(Slower)
Current Ratio
4.43
This Stock
vs
4.56
Sector Avg
-2.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACLX
Arcellx, Inc.
|
BEARISH | $6.69B | - | -53.4% | -% | $114.39 | |
|
HQY
HealthEquity, Inc.
|
NEUTRAL | $6.66B | 31.69 | 10.2% | 16.4% | $77.96 | Compare |
|
RGEN
Repligen Corporation
|
NEUTRAL | $6.64B | 137.0 | 2.4% | 6.6% | $117.82 | Compare |
|
GRFS
Grifols, S.A.
|
NEUTRAL | $6.74B | 12.83 | 6.2% | 5.3% | $8.21 | Compare |
|
KYMR
Kymera Therapeutics, Inc.
|
NEUTRAL | $6.94B | - | -25.8% | -% | $85.05 | Compare |
ACLX
Arcellx, Inc.
BEARISH
Mkt Cap
$6.7B
P/E
-
ROE
-53.4%
Price
$114.39
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | ELGHANDOUR RAMI | Chief Executive Officer | Gift | 101,164 | - |
| 2026-02-27 | ELGHANDOUR RAMI | Chief Executive Officer | Sale | 89,916 | $10,243,267 |
| 2026-02-25 | GILSON MICHELLE | Chief Financial Officer | Sale | 11,219 | $1,276,954 |
| 2026-02-19 | GILSON MICHELLE | Chief Financial Officer | Sale | 8,384 | $572,568 |
| 2026-02-17 | GILSON MICHELLE | Chief Financial Officer | Sale | 11,291 | $784,783 |
| 2026-02-11 | ELGHANDOUR RAMI | Chief Executive Officer | Gift | 218,500 | - |
| 2026-02-11 | ELGHANDOUR RAMI | Chief Executive Officer | Gift | 198,000 | - |
| 2026-01-20 | LUBNER DAVID CHARLES | Director | Option Exercise | 6,000 | $37,680 |
| 2026-01-20 | LUBNER DAVID CHARLES | Director | Sale | 6,000 | $450,000 |
| 2026-01-14 | HEERY CHRISTOPHER RYAN | Officer | Sale | 5,882 | $402,997 |
| 2026-01-13 | HEERY CHRISTOPHER RYAN | Officer | Sale | 7,437 | $487,213 |
| 2026-01-12 | HEERY CHRISTOPHER RYAN | Officer | Sale | 6,131 | $393,286 |
| 2026-01-06 | ELGHANDOUR RAMI | Officer and Director | Stock Award | 164,548 | - |
| 2026-01-06 | HEERY CHRISTOPHER RYAN | Officer | Stock Award | 42,605 | - |
| 2026-01-06 | GILSON MICHELLE | Chief Financial Officer | Stock Award | 56,366 | - |
ELGHANDOUR RAMI
Chief Executive Officer
2026-03-04
101,164 shares
ELGHANDOUR RAMI
Chief Executive Officer
2026-02-27
89,916 shares
·
$10,243,267
GILSON MICHELLE
Chief Financial Officer
2026-02-25
11,219 shares
·
$1,276,954
GILSON MICHELLE
Chief Financial Officer
2026-02-19
8,384 shares
·
$572,568
GILSON MICHELLE
Chief Financial Officer
2026-02-17
11,291 shares
·
$784,783
ELGHANDOUR RAMI
Chief Executive Officer
2026-02-11
218,500 shares
ELGHANDOUR RAMI
Chief Executive Officer
2026-02-11
198,000 shares
LUBNER DAVID CHARLES
Director
2026-01-20
6,000 shares
·
$37,680
LUBNER DAVID CHARLES
Director
2026-01-20
6,000 shares
·
$450,000
HEERY CHRISTOPHER RYAN
Officer
2026-01-14
5,882 shares
·
$402,997
HEERY CHRISTOPHER RYAN
Officer
2026-01-13
7,437 shares
·
$487,213
HEERY CHRISTOPHER RYAN
Officer
2026-01-12
6,131 shares
·
$393,286
ELGHANDOUR RAMI
Officer and Director
2026-01-06
164,548 shares
HEERY CHRISTOPHER RYAN
Officer
2026-01-06
42,605 shares
GILSON MICHELLE
Chief Financial Officer
2026-01-06
56,366 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
14 analysts
Guggenheim
2026-02-26
Buy
Neutral
Truist Securities
2026-02-24
Buy
Hold
Evercore ISI Group
2026-02-24
Outperform
In-Line
UBS
2026-02-24
Buy
Neutral
Citigroup
2026-02-24
Buy
Neutral
Leerink Partners
2026-02-24
Outperform
Market Perform
Stifel
2026-02-24
Buy
Hold
HC Wainwright & Co.
2026-02-23
Buy
Neutral
Baird
2026-02-23
Outperform
Neutral
Needham
2026-02-23
Buy
Hold
Past News Coverage
Recent headlines mentioning ACLX from our newsroom.
Newest → oldest
No matching news yet.